贝瑞基因收盘上涨10.01%，最新市净率2.96，总市值49.35亿元

Group 1 - The core viewpoint of the news highlights the recent performance and market position of Berry Genomics, noting a significant stock price increase and a low market-to-book ratio [1] - On May 13, Berry Genomics closed at 13.96 yuan, up 10.01%, with a market capitalization of 4.935 billion yuan and a price-to-book ratio of 2.96, marking a new low in 31 days [1] - The company experienced a net inflow of 137.79 million yuan in main funds on May 13, with a total inflow of 102.66 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, offering related equipment and reagent sales [1] - The company provides comprehensive solutions through "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The latest financial report for Q1 2025 shows the company achieved revenue of 218 million yuan, a year-on-year decrease of 22.08%, with a net loss of approximately 6.46 million yuan, reflecting a year-on-year decline of 178.47% and a gross profit margin of 49.48% [1] Group 3 - In comparison to industry averages, Berry Genomics has a TTM PE ratio of -23.83 and a static PE ratio of -25.65, with a market capitalization of 4.935 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 50.06 and the static PE at 45.92, indicating that Berry Genomics is underperforming relative to its peers [2] - The industry median market capitalization is 4.795 billion yuan, suggesting that Berry Genomics is positioned within a competitive landscape [2]